{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 1.1, Synopsis', 'Study rationale updated based on shortened study', 'To reflect', 'Section 1.2, Schema', 'design; minor updates to clarify several objectives', 'shortened study', 'Section 1.3, Schedule of', 'and endpoints and removal of other objectives and', 'design from 104', 'Activities', 'endpoints to reflect updated study design; overall', 'weeks to 52 weeks', 'Section 2.1, Study Rationale', 'design section and Intervention groups and', 'Section 3, Objectives and', 'duration sections were updated to reflect a 52', 'Endpoints', 'week study. Participants on CAR will no longer', 'Section 4.1, Overall Design', 'switch at Week 52 as the study will end. Only', 'Section 4.2, Number of', 'participants in the D3 arm will have the opportunity', 'Participants', 'to enter a continuation phase; number of', 'Section 4.3, Participant and', 'participants section was updated to reflect current', 'Study Completion', 'goal to include 20% women and include a goal of', 'Section 4.4, Scientific', 'approximately 20% participants on', 'Rationale for Study Design', 'efavirenz/emtricitabine/tenofovir disoproxil', 'Section 6.8, Treatment after', 'fumarate and approximately 20% aged >50 years;', 'the end of the study', 'study schematic updated based on shortened', 'Section 7.2, Withdrawal from', 'study design; schedule of activities updated based', 'the Study', 'on shortened study design; the SDM will now be', 'Section 8.1.3, Exploratory', 'collected every 24 weeks during the continuation', 'Efficacy Endpoints', 'phase to address shortened study design; updated', 'SoA footnotes as required.', 'Section 1.3, Schedule of', 'Removed all text related to permitting participants', 'To reflect updated', 'Activities', 'to remain on study if they become pregnant;', 'study design to', 'Section 1.4, Pregnancy SoA', 'removed risk related to use in pregnancy as this is', 'remove the option', 'Section 2.3, Risk/Benefit', 'no longer permitted and added risk related to', 'to remain on the', 'Assessment', 'Neural Tube Defects; updated all sections to', 'study if the', 'Section 4.1, Overall Design', 'remove information related to PK sampling in', 'participant', 'Section 4.3, Participant and', 'pregnant participants; updated withdrawal criteria', 'becomes pregnant;', 'Study Completion', 'related to pregnancy; contraceptive guidance', 'Updated to manage', 'Section 4.4, Scientific', 'updated to remove double barrier method and', 'and mitigate risks', 'Rationale for Study Design', 'collection of pregnancy information updated', 'following', 'Section 6.8, Treatment after', 'identification of a', 'the end of the study', 'potential safety', 'Section 7.2, Withdrawal from', 'issue related to', 'the Study', 'neural tube defects', 'Section 8.2.6, Pregnancy', 'in infants born to', 'Section 8.2.7, Infant Outcomes', 'women with', 'Section 8.2.8, Lactation', 'exposure to', 'Section 8.5, Pharmocokinetics', 'dolutegravir at the', 'Section 9, Statistical', 'time of conception.', 'Considerations', 'Section 11.4. Appendix 4:', 'Contraceptive Guidance and', 'Collection of Pregnancy', 'Information', 'Section 5, Study population', 'Inclusion criteria 5 and 6 and exclusion criterion 28', 'To further clarify', 'updated', 'the study', 'population', 'Section 1.1, Synopsis', 'Added reference to and details of new CVW or', 'A CVW or PVW', 'Section 4.1, Overall Design', 'PVW sub-study', 'sub-study was', 'Section 7.1.1.2 Managing', 'added to collect', '166']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Participants Meeting', 'additional data on', 'Precautionary Virologic', 'participants who', 'Withdrawal (PVW) or', 'withdraw from', 'Confirmed Virologic', '208090 study for', 'Withdrawal (CVW) Criteria', 'meeting CVW or', 'PVW criteria', 'Section 11.2, Appendix 2: A', 'Sub-study of Virologic', 'Response to Subsequent ART', 'after Discontinuation from', '208090 for Meeting CVW or', 'PVW Criteria', 'Section 8.8, Biomarkers', 'Updated to add Urine RBP/creatinine ratio and', 'To further clarify', 'Section 11.7, Appendix 7', 'Urine B2M/creatinine ratio and clarify that RBP and', 'what biomarkers', 'Clinical Laboratory Tests', 'B2M will be urine sample only and not blood', 'will be collected', 'during this study', 'Section 1.3, Schedule of', 'Updated to add viral DNA quantitation and include', 'To allow for', 'Activities', 'language around collection of PBMCs/whole blood', 'additional Virology', 'Section 8.10.1, HIV-1', 'exploratory analysis', 'Exploratory Analysis', 'Section 11.9, Appendix 9: Liver', 'Liver safety requirements were updated', 'Updated to align', 'Safety: Required Actions and', 'with current ViiV', 'Follow-up Assessments and', 'Safety and', 'Study Intervention Restart', 'Labelling', 'Guidelines', 'Committee (VSLC)', 'guidelines', 'Title Page, Authors', 'Authors list updated to add', 'PPD', 'To reflect minor', 'Section 2, Introduction', 'PPD', 'and PPD', 'updates for clarity', 'Section 2.2, Background', 'and to remove PPD', 'PPD', 'and', 'and additional', 'Section 8.1, Efficacy', 'PPD', 'Clarifying details regarding PK', 'recent data added', 'Assessments', 'collection for overdose added; Section 8.9 Heading', 'for completeness', 'Section 8.5, Pharmacokinetics', 'updated to include outcomes research; Table 2', 'Section 8.9 Health Economics', 'updated to add recent studies and other minor', 'and Outcomes Research', 'changes; references updated', 'Section 9, Statistical', 'Considerations', 'Section 10, References', 'Amendment 03, 25-MAR-2019', 'Overall Rationale for the Amendment: A global amendment, for administrative', 'purposes, applicable to all participating countries. Edits to increase clarity around', 'collection of virology specimens for additional testing, the timing of the eCSSRS', 'questionnaire in relation to medication administration, and follow-up for AEs were made.', 'Additional changes were made to correct editing errors related to the tables for liver', 'stopping criteria, which contained both GSK and ViiV-specific stopping criteria. This', 'amendment removed the GSK information. No changes were made to the ViiV-specific', 'criteria that was included in the previous version.', '167']\n\n###\n\n", "completion": "END"}